Genovis

Genovis Equity

The The Equity of Genovis (GENO.ST) as of Nov 4, 2026 is 271.52 M SEK. In the previous year, The Equity was 227.97 M SEK — a change of 19.10% (higher).

Equity

271.52 MSEK

YoY

19.10%

Last updated:

In 2025, Genovis's equity was 271.52 M SEK, a 19.10% increase from the 227.97 M SEK equity in the previous year.

The Genovis Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
26.07 M SEK
Jan 1, 2019
35.62 M SEK
Jan 1, 2020
87.17 M SEK
Jan 1, 2021
113.99 M SEK
Jan 1, 2022
125.65 M SEK
Jan 1, 2023
190.81 M SEK
Jan 1, 2024
227.97 M SEK
Jan 1, 2025
271.52 M SEK
The Genovis Equity history
YEAREquityYoY
271.52 MSEK+19.10%
227.97 MSEK+19.48%
190.81 MSEK+51.86%
125.65 MSEK+10.23%
113.99 MSEK+30.78%
87.17 MSEK+144.70%
35.62 MSEK+36.63%
26.07 MSEK+43.35%
18.19 MSEK+16.99%
15.55 MSEK+76.21%
8.82 MSEK-39.51%
14.58 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genovis Stock analysis

What does Genovis do? Genovis AB is a Swedish company that offers biotechnology solutions for drug research and diagnostic industries. The company was founded in Lund, Sweden in 1999 and currently employs over 30 employees. Genovis began with the development of enzymes for protein-based therapeutics, but over time expanded its business to include enzymes for improved analysis methods in mass spectrometry. Genovis has become a leading provider of innovative enzyme solutions and proteomics tools for biomedical research. The company's business model is based on providing specially developed enzymes and proteomics tools to companies in drug research and diagnostic industries. Genovis has two main business areas: marketing enzymes and providing peptide synthesis services. The first business area is the marketing of enzymes for the separation of glycosylated proteins in mass spectrometry. The company develops and produces these enzymes for various applications such as Alzheimer's research, cancer research, and infectious diseases. Genovis is also an important provider of enzymes for the investigation of antibody-drug conjugates used in novel therapeutic approaches. The second business area is providing peptide synthesis services. The company also has a diversified biotechnology infrastructure and offers analysis and synthesis services for peptides in various fields, such as immunotherapy and diagnostics. Genovis' product portfolio includes a variety of enzymes that have broad application in drug research and diagnostic industries. This includes enzymes for antibody proteolysis, enzymes for the synthesis of glycoconjugates, and enzymes for conjugated protein analysis. In addition, the company also offers specialized kits for protein analysis. Genovis kits always include all necessary components such as proteases, buffer systems, and instructions to conduct the offered experiments. In conclusion, Genovis is a leading company in the biotechnology industry that offers innovative enzyme solutions and proteomics tools for a variety of applications in medical research and diagnostics. With its diversified biotechnology infrastructure and dedicated employees, the company can meet the growing needs of its customers in the science and industry sectors and has become a key partner in the healthcare industry. Genovis is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Genovis's Equity

Genovis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Genovis's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Genovis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Genovis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Genovis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Genovis stock

The Equity of Genovis is 271.52 M SEK in 2025.

The Equity of Genovis changed from 227.97 M SEK to 271.52 M SEK, representing a 19.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Genovis since 2006 – with annual values, charts, and detailed analysis.

The Equity's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Genovis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genovis

All Key Metrics — Genovis